SCIg is a prescription only medication that may be used in an
admitted patient or outpatient setting1.
Subcutaneous immunoglobulin (SCIg) is a solution of human plasma
proteins and in particular IgG antibodies with a broad spectrum
of antibody activity. SCIg is prepared from large pools of human
plasma and contains the typical IgG antibodies found in the
Approved access conditions for SCIg
SCIg is only approved for patients with a medical
- Where there is support for use cited in the Criteria
for the clinical use of immunoglobulin in Australia,
- primary immunodeficiency diseases
with antibody deficiency
- specific antibody deficiency
- acquired hypogammaglobulinaemia
secondary to haematological malignancies (chronic lymphocytic
leukaemia, multiple myeloma, non-Hodgkin lymphoma and other
relevant malignancies, and post-haemopoietic stem cell
- secondary hypogammaglobulinaemia
(including iatrogenic immunodeficiency)
- Being treated by a clinical specialist within a hospital
based SCIg program (see below), where the hospital provides
access to all resources and takes full accountability for the
management and use of the SCIg product, at no additional cost to
- Following a patient-specific SCIg request submitted to, and
authorised by, the Australian Red Cross Lifeblood (Lifeblood).
The Victorian Department of Health and Human Services (DHHS) has outlined it's commitment to funding SCIg in the department's policy and funding guidelines 2019-20.
The department will fund public health services $680 per quarter for each patient supplied with SCIg. With $600 provided to the 'Administering Facility' and $80 to the 'Dispensing Facility, as identified by BloodSTAR data.
The funding covers the ongoing costs associated with SCIg service delivery including-patient training, staffing costs, consumables, pumps and dispensing fees.
The Blood Matters team has a SCIg project nurse to assist in the state-wide rollout of SCIg in Victoria.
The key objective of the SCIg project nurse is to support health services to develop local policies and guidelines aligned with the National Blood Authority guidelines and the Criteria for immunoglobulin use in Australia.
More information on SCIg can be found at the National Blood Authority website3.
1 Hospital Circular
2 Australian Red Cross Lifeblood
3 National Blood
SCIg program tools and resources
Information, tools, links and resources to support Australia’s National Blood Authority national SCIg program.
Visit tools and resources
SCIg Community of Practice contacts
Contact details of the nurses support hospital based SCIg programs.